TASLY(SH:600535) Xin Lang Cai Jing·2025-09-22 08:34Core Viewpoint - Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for its recombinant human urokinase (brand name: Puyouke) to be used for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurology/psychiatry sector [1] Group 1 - The product Puyouke is currently the only approved recombinant human urokinase product in China [1] - Puyouke is the first Class 1 biological innovative drug supported by the "Major New Drug Creation" technology major project during the "11th Five-Year Plan" period [1] - The drug is already approved for the treatment of acute ST-segment elevation myocardial infarction, and the new indication enhances the company's offerings in the neurological field [1]